iCAD, Inc. (NASDAQ:ICAD – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 786,500 shares, a drop of 13.5% from the August 15th total of 909,700 shares. Approximately 3.3% of the shares of the company are short sold. Based on an average trading volume of 1,400,000 shares, the short-interest ratio is currently 0.6 days.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on ICAD shares. StockNews.com started coverage on iCAD in a research note on Thursday, August 17th. They issued a “hold” rating on the stock. Lake Street Capital upped their price objective on shares of iCAD from $2.50 to $5.00 in a research note on Wednesday, July 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.
Institutional Trading of iCAD
iCAD Trading Down 3.9 %
Shares of ICAD traded down $0.08 during mid-day trading on Tuesday, hitting $1.86. 341,097 shares of the company traded hands, compared to its average volume of 608,348. The stock has a market capitalization of $47.21 million, a price-to-earnings ratio of -3.79 and a beta of 1.32. The business has a 50-day moving average of $2.49 and a 200 day moving average of $1.82. iCAD has a one year low of $1.05 and a one year high of $3.97.
iCAD (NASDAQ:ICAD – Get Free Report) last posted its quarterly earnings results on Monday, August 14th. The technology company reported ($0.07) earnings per share for the quarter. iCAD had a negative net margin of 51.13% and a negative return on equity of 36.14%. The company had revenue of $5.87 million during the quarter.
iCAD Company Profile
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography.
- Five stocks we like better than iCAD
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Hold-It-Forever AutoZone Pulls into Buy Zone
- How to Invest in Apparel Stocks
- Virtual Riches: 3 Stocks Leading the VR Revolution
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 5 eCommerce Companies that need to be on Your Watch List
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.